Cinacalcet HCl and Concurrent Low-dose Vitamin D Improves Treatment of Secondary Hyperparathyroidism in Dialysis Patients Compared with Vitamin D Alone | Zendy

Steven Fishbane | Zendy; Warren Shapiro | Zendy; Dalila B. Corry | Zendy; Steven L. Vicks | Zendy; Michael Roppolo | Zendy; Kenneth Rappaport | Zendy; Ling Xiang | Zendy; William G. Goodman | Zendy; Stewart A. Turner | Zendy; Chaim Charytan | Zendy

Open Access

Cinacalcet HCl and Concurrent Low-dose Vitamin D Improves Treatment of Secondary Hyperparathyroidism in Dialysis Patients Compared with Vitamin D Alone

Author(s) -

Steven Fishbane,

Warren Shapiro,

Dalila B. Corry,

Steven L. Vicks,

Michael Roppolo,

Kenneth Rappaport,

Ling Xiang,

William G. Goodman,

Stewart A. Turner,

Chaim Charytan

Publication year - 2008

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.01040308

Subject(s) - cinacalcet , medicine , vitamin d and neurology , secondary hyperparathyroidism , kidney disease , hyperparathyroidism , dialysis , parathyroid hormone , calcimimetic , urology , phosphate binder , endocrinology , vitamin d deficiency , hemodialysis , calcium , hyperphosphatemia

Patients with chronic kidney disease (CKD) receiving dialysis often develop secondary hyperparathyroidism with disturbed calcium and phosphorus metabolism. The National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (KDOQI) was established to guide treatment practices for these disorders. The ACHIEVE study was designed to test two treatment strategies for achieving KDOQI goals.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research